Event Title
Location
Philadelphia, PA
Start Date
11-5-2022 1:00 PM
End Date
11-5-2022 4:00 PM
Description
Introduction
This study is designed to analyze experiences of the PCOM Philadelphia community regarding COVID19 vaccination. While previous studies have examined specific adverse reactions to this treatment, the present survey allowed participants to indicate which vaccine they received (Pfizer-BioNTech, Moderna mRNA-1273, or J&J/Janssen) and how many doses, as well as demographic information, underlying health conditions, prior COVID infection and symptoms, and any reaction to the COVID vaccination. Prior COVID infection is taken into consideration in this survey, as previous research has indicated that 70% of people who had not been previously infected reported Pfizer vaccine side effects, while 95% of people who had already been infected reported at least one Pfizer vaccination side effect. Results of this study will provide an enhanced understanding of factors correlating COVID vaccination with subsequent adverse events, and the impact of experiencing these events upon booster vaccination hesitancy.
Methods
A 16-question survey was created using SurveyMonkey and distributed via email to students, faculty, and staff at the Philadelphia campus of the Philadelphia College of Osteopathic Medicine. Survey questions include:
-
Are you vaccinated against COVID19?
-
Which vaccination did you receive and how many doses?
-
Age range, gender, race, blood type, smoking history, and underlying health conditions.
-
History of positive COVID test prior to vaccination, reactions to the COVID infection and/or vaccination, and booster status.
-
Participants who indicated that they had either a previous COVID19 infection or a reaction to the COVID19 vaccination are asked to specify which reactions were experienced.
Results were collected from March 1 to 22, 2022. Data will be reviewed in order to identify correlations with COVID vaccination and demographic information, underlying health conditions, prior COVID infection and reactions to COVID vaccination.
Results
Of a total of 4,053 persons, responses were received from 758 (18.7%). Additional details will be presented on Research Day, May 11, 2022.
Discussion - Pending data review.
Embargo Period
6-1-2022
Included in
COVID Vaccine ADR Survey
Philadelphia, PA
Introduction
This study is designed to analyze experiences of the PCOM Philadelphia community regarding COVID19 vaccination. While previous studies have examined specific adverse reactions to this treatment, the present survey allowed participants to indicate which vaccine they received (Pfizer-BioNTech, Moderna mRNA-1273, or J&J/Janssen) and how many doses, as well as demographic information, underlying health conditions, prior COVID infection and symptoms, and any reaction to the COVID vaccination. Prior COVID infection is taken into consideration in this survey, as previous research has indicated that 70% of people who had not been previously infected reported Pfizer vaccine side effects, while 95% of people who had already been infected reported at least one Pfizer vaccination side effect. Results of this study will provide an enhanced understanding of factors correlating COVID vaccination with subsequent adverse events, and the impact of experiencing these events upon booster vaccination hesitancy.
Methods
A 16-question survey was created using SurveyMonkey and distributed via email to students, faculty, and staff at the Philadelphia campus of the Philadelphia College of Osteopathic Medicine. Survey questions include:
-
Are you vaccinated against COVID19?
-
Which vaccination did you receive and how many doses?
-
Age range, gender, race, blood type, smoking history, and underlying health conditions.
-
History of positive COVID test prior to vaccination, reactions to the COVID infection and/or vaccination, and booster status.
-
Participants who indicated that they had either a previous COVID19 infection or a reaction to the COVID19 vaccination are asked to specify which reactions were experienced.
Results were collected from March 1 to 22, 2022. Data will be reviewed in order to identify correlations with COVID vaccination and demographic information, underlying health conditions, prior COVID infection and reactions to COVID vaccination.
Results
Of a total of 4,053 persons, responses were received from 758 (18.7%). Additional details will be presented on Research Day, May 11, 2022.
Discussion - Pending data review.
Comments
Presented by Demetria Ruhl.